相似文献
1
Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons.
Brain Pathol. 2005 Apr;15(2):134-8. doi: 10.1111/j.1750-3639.2005.tb00509.x.
2
Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity.
Am J Pathol. 2005 Apr;166(4):1163-72. doi: 10.1016/s0002-9440(10)62336-x.
3
Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis.
Am J Pathol. 2015 Jan;185(1):230-9. doi: 10.1016/j.ajpath.2014.09.016. Epub 2014 Nov 15.
4
Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells.
PLoS One. 2016 Jan 29;11(1):e0147721. doi: 10.1371/journal.pone.0147721. eCollection 2016.
5
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease.
J Neurosci. 2005 Nov 2;25(44):10180-7. doi: 10.1523/JNEUROSCI.3591-05.2005.
6
Inhibition of STAT3- and MAPK-dependent PGE synthesis ameliorates phagocytosis of fibrillar β-amyloid peptide (1-42) via EP2 receptor in EMF-stimulated N9 microglial cells.
J Neuroinflammation. 2016 Nov 21;13(1):296. doi: 10.1186/s12974-016-0762-9.
7
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity.
Glia. 2005 Oct;52(1):70-7. doi: 10.1002/glia.20220.
8
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow.
Am J Pathol. 2010 Jul;177(1):346-54. doi: 10.2353/ajpath.2010.090840. Epub 2010 Jun 3.
9
CD14 and Toll-Like Receptor 4 Promote Fibrillar Aβ42 Uptake by Microglia Through A Clathrin-Mediated Pathway.
J Alzheimers Dis. 2019;68(1):323-337. doi: 10.3233/JAD-180904.
10
DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain.
Am J Pathol. 2009 Oct;175(4):1622-30. doi: 10.2353/ajpath.2009.090443. Epub 2009 Sep 3.
引用本文的文献
1
Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis.
J Med Chem. 2023 Jul 27;66(14):9313-9324. doi: 10.1021/acs.jmedchem.3c00655. Epub 2023 Jul 17.
2
Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease.
J Neuroinflammation. 2022 Aug 17;19(1):206. doi: 10.1186/s12974-022-02565-0.
3
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease.
Curr Neuropharmacol. 2022;20(1):126-146. doi: 10.2174/1570159X19666210826130210.
4
Microbial involvement in Alzheimer disease development and progression.
Mol Neurodegener. 2020 Jul 24;15(1):42. doi: 10.1186/s13024-020-00378-4.
5
Calcium Ions Stimulate the Hyperphosphorylation of Tau by Activating Microsomal Prostaglandin E Synthase 1.
Front Aging Neurosci. 2019 May 9;11:108. doi: 10.3389/fnagi.2019.00108. eCollection 2019.
6
Melatonin Attenuates Manganese and Lipopolysaccharide-Induced Inflammatory Activation of BV2 Microglia.
Neurochem Res. 2017 Feb;42(2):656-666. doi: 10.1007/s11064-016-2122-7. Epub 2016 Nov 30.
7
Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration.
Behav Brain Funct. 2015 Feb 18;11:8. doi: 10.1186/s12993-015-0054-z.
8
Neuroinflammation in Alzheimer's disease.
Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5.
9
Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.
Expert Opin Ther Pat. 2015 Jul;25(7):837-44. doi: 10.1517/13543776.2015.1025752. Epub 2015 Mar 15.
10
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
Neurobiol Dis. 2015 Apr;76:126-136. doi: 10.1016/j.nbd.2014.12.032. Epub 2015 Jan 17.
本文引用的文献
1
Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity.
Am J Pathol. 2005 Apr;166(4):1163-72. doi: 10.1016/s0002-9440(10)62336-x.
2
Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease.
Neurology. 2005 Feb 8;64(3):545-7. doi: 10.1212/01.WNL.0000150591.33787.A4.
3
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study.
BMC Geriatr. 2005 Jan 12;5:2. doi: 10.1186/1471-2318-5-2.
4
Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo.
J Neuroinflammation. 2004 Oct 21;1(1):20. doi: 10.1186/1742-2094-1-20.
5
Coxibs and cardiovascular disease.
N Engl J Med. 2004 Oct 21;351(17):1709-11. doi: 10.1056/NEJMp048288. Epub 2004 Oct 6.
6
Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.
J Pharmacol Exp Ther. 2005 Jan;312(1):399-406. doi: 10.1124/jpet.104.073965. Epub 2004 Aug 30.
7
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia.
J Neurosci. 2004 Jan 7;24(1):257-68. doi: 10.1523/JNEUROSCI.4485-03.2004.
8
Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum.
J Neurochem. 2003 Dec;87(6):1518-26. doi: 10.1046/j.1471-4159.2003.02120.x.
9
The LPS receptor (CD14) links innate immunity with Alzheimer's disease.
FASEB J. 2004 Jan;18(1):203-5. doi: 10.1096/fj.03-0364fje. Epub 2003 Nov 3.
10
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
J Neurosci. 2003 Aug 20;23(20):7504-9. doi: 10.1523/JNEUROSCI.23-20-07504.2003.
Zotero 插件